Document is current

Article History

Received: 2 August 2024

Accepted: 6 December 2024

First Online: 8 January 2025

Declarations

:

: Tobias Alexander has received consulting fees from Amgen; honoraria from AbbVie, AstraZeneca, GSK, Neovii and Pfizer; support for attending meetings, and/or travel support, from AbbVie, Neovii and Pfizer; and study support from Janssen-Cilag. Philipp Sewerin has received consulting fees from Amgen; honoraria and support for attending meetings, and/or travel support, from AbbVie, Alfasigma S.p.A., Amgen, Axiom Health, Biogen, Bristol-Myers Squibb, Celgene, Chugai, Gilead Sciences, Hexal, Janssen-Cilag, Johnson & Johnson, Lilly, mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche, Sanofi-Genzyme, Swedish Orphan Biovitrum and UCB Pharma. Anja Strangfeld has received honoraria from AbbVie, Galapagos, Lilly, Janssen, Pfizer and Takeda; is Chair of the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Data Monitoring Committee (voluntary role); and is on the Data Monitoring Committee Board of the Lupus Best Study (voluntary role). Marcus Schulte and Eva Schrom are employees of, and hold stocks in, Amgen. Julia Borchert and Tarcyane Barata Garcia are employees of WIG2 GmbH.

: This study used anonymised secondary data (i.e. healthcare insurance claims data); hence, ethics approval and consent to participate were not applicable. Patient consent for publication was also not applicable.